GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » Equity-to-Asset

Checkpoint Therapeutics (Checkpoint Therapeutics) Equity-to-Asset : -2.43 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Checkpoint Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-13.05 Mil. Checkpoint Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $5.38 Mil. Therefore, Checkpoint Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -2.43.

The historical rank and industry rank for Checkpoint Therapeutics's Equity-to-Asset or its related term are showing as below:

CKPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.43   Med: 0.7   Max: 0.92
Current: -2.43

During the past 9 years, the highest Equity to Asset Ratio of Checkpoint Therapeutics was 0.92. The lowest was -2.43. And the median was 0.70.

CKPT's Equity-to-Asset is ranked worse than
94.7% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs CKPT: -2.43

Checkpoint Therapeutics Equity-to-Asset Historical Data

The historical data trend for Checkpoint Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics Equity-to-Asset Chart

Checkpoint Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.70 0.83 0.53 -1.47 -2.43

Checkpoint Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.47 -3.76 -2.79 -8.59 -2.43

Competitive Comparison of Checkpoint Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Checkpoint Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkpoint Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's Equity-to-Asset falls into.



Checkpoint Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Checkpoint Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-13.047/5.378
=-2.43

Checkpoint Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-13.047/5.378
=-2.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Checkpoint Therapeutics  (NAS:CKPT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Checkpoint Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkpoint Therapeutics (Checkpoint Therapeutics) Business Description

Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Executives
William Garrett Gray officer: See Remarks 2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Oliviero James F Iii director, officer: CEO, President and Director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon director C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman director 464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen director 2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Checkpoint Therapeutics (Checkpoint Therapeutics) Headlines